{"id":"multi-allergen-oral-immunotherapy","safety":{"commonSideEffects":[{"rate":null,"effect":"Oral pruritus"},{"rate":null,"effect":"Throat irritation"},{"rate":null,"effect":"Gastrointestinal symptoms (nausea, abdominal discomfort)"},{"rate":null,"effect":"Mild allergic reactions"},{"rate":null,"effect":"Anaphylaxis (rare)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The therapy works by administering gradually increasing doses of multiple allergen extracts orally, which shifts the immune response from IgE-mediated allergic reactions toward regulatory T cell activation and IgG-blocking antibody production. This process, called oral immunological tolerance, reduces allergic symptoms and the risk of anaphylaxis upon natural allergen exposure. The multi-allergen formulation targets several common environmental or food allergens simultaneously.","oneSentence":"Multi-allergen oral immunotherapy desensitizes the immune system to multiple allergens by gradually exposing patients to increasing doses of allergen extracts taken by mouth, promoting immune tolerance.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:22:21.165Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"IgE-mediated allergic disease to multiple allergens"},{"name":"Food and/or environmental allergies (specific allergens under investigation)"}]},"trialDetails":[{"nctId":"NCT03881696","phase":"PHASE3","title":"Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic Participants","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-07-22","conditions":"Peanut Allergy, Multi-food Allergy","enrollment":471},{"nctId":"NCT03799328","phase":"PHASE2","title":"Low Dose Multi-OIT for Food Allergy (LoMo)","status":"COMPLETED","sponsor":"The Hospital for Sick Children","startDate":"2019-05-23","conditions":"Food Allergy","enrollment":18},{"nctId":"NCT04856865","phase":"PHASE1, PHASE2","title":"ADP101 for Oral Immunotherapy in Food-Allergic Children and Adults","status":"COMPLETED","sponsor":"Alladapt Immunotherapeutics, Inc.","startDate":"2021-04-20","conditions":"Food Allergy","enrollment":73},{"nctId":"NCT05243719","phase":"PHASE1, PHASE2","title":"Open-label Extension Study of ADP101","status":"TERMINATED","sponsor":"Alladapt Immunotherapeutics, Inc.","startDate":"2022-03-14","conditions":"Food Allergy","enrollment":45},{"nctId":"NCT06103656","phase":"PHASE2","title":"E-B-FAHF-2, Multi OIT and Xolair for Food Allergy","status":"COMPLETED","sponsor":"New York Medical College","startDate":"2016-08-20","conditions":"Food Allergy","enrollment":33},{"nctId":"NCT02879006","phase":"PHASE2","title":"E-B-FAHF-2, Multi OIT and Xolair (Omalizumab) for Food Allergy","status":"UNKNOWN","sponsor":"Xiu-Min Li","startDate":"2016-08","conditions":"Food Allergy","enrollment":33},{"nctId":"NCT03181009","phase":"PHASE2","title":"Multi OIT to Test Immune Markers After Minimum Maintenance Dose","status":"COMPLETED","sponsor":"Kari Christine Nadeau, MD PhD","startDate":"2017-07-31","conditions":"Food Allergy","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":13,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Multi-Allergen OIT"],"phase":"phase_3","status":"active","brandName":"Multi-Allergen Oral Immunotherapy","genericName":"Multi-Allergen Oral Immunotherapy","companyName":"National Institute of Allergy and Infectious Diseases (NIAID)","companyId":"national-institute-of-allergy-and-infectious-diseases-niaid","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Multi-allergen oral immunotherapy desensitizes the immune system to multiple allergens by gradually exposing patients to increasing doses of allergen extracts taken by mouth, promoting immune tolerance. Used for IgE-mediated allergic disease to multiple allergens, Food and/or environmental allergies (specific allergens under investigation).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}